Inicio
Resultado de la búsqueda
2 búsqueda de la palabra clave 'Biomarkers'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas : a Histologic Study / Luis Vicente Syro Moreno
Título : Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas : a Histologic Study Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2017 Títulos uniformes : Pathology and Oncology Research Idioma : Inglés (eng) Palabras clave : Biomarkers pathology pituitary adenoma microvascularity vasculogenic mimicry Resumen : The term “vasculogenic mimicry” (VM) refers to the phenomenon in which vascular-like channels, which are not lined by endothelial cells, are formed in tumors. Since its discovery in 1999, it has been observed in several tumor types and is proposed to provide blood perfusion to tumors in absence of co-apted or neo-angiogenic blood vessels. Pituitary tumors are generally slow growing, benign adenomas which are less vascularized than the normal pituitary gland. To date, VM in pituitary adenomas has not been described. In this histological study, we assessed the presence of VM in a series of surgically resected clinically non-functioning pituitary adenomas (NFPAs) using CD34 and Periodic Acid-Schiff (PAS) double staining. To identify VM, slides were assessed for the presence of CD34-negative and PAS-positive channels indicating that they were not lined by endothelial cells. The histological staining pattern suggestive of VM was noted in 22/49 (44.9%) of the specimens studied. VM was observed in both recurring and non-recurring NFPAs. The incidence of VM present varied from case to case and within groups. There was no association between the presence of VM and gender, tumor size, Ki-67 index, recurrence or cavernous sinus invasion. VM was not noted in cases of non-tumorous pituitaries. Our findings suggest the existence of a complementary perfusion system in pituitary adenomas, implying potential clinical implications with respect to response to therapy and clinical course. Further research is warranted to confirm the presence of VM in pituitary adenomas to elucidate its clinical relevance in patients diagnosed with a pituitary adenoma. Mención de responsabilidad : Joseph Di Michele, Fabio Rotondo, Kalman Kovacs, Luis V Syro, George M Yousef, Michael D Cusimano, Antonio Di Ieva Referencia : Pathol Oncol Res. 2017 Oct;23(4):803-809. DOI (Digital Object Identifier) : 10.1007/s12253-017-0196-4 PMID : 28084580 En línea : https://link.springer.com/article/10.1007%2Fs12253-017-0196-4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4030 Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas : a Histologic Study [documento electrónico] / Luis Vicente Syro Moreno, . - 2017.
Obra : Pathology and Oncology Research
Idioma : Inglés (eng)
Palabras clave : Biomarkers pathology pituitary adenoma microvascularity vasculogenic mimicry Resumen : The term “vasculogenic mimicry” (VM) refers to the phenomenon in which vascular-like channels, which are not lined by endothelial cells, are formed in tumors. Since its discovery in 1999, it has been observed in several tumor types and is proposed to provide blood perfusion to tumors in absence of co-apted or neo-angiogenic blood vessels. Pituitary tumors are generally slow growing, benign adenomas which are less vascularized than the normal pituitary gland. To date, VM in pituitary adenomas has not been described. In this histological study, we assessed the presence of VM in a series of surgically resected clinically non-functioning pituitary adenomas (NFPAs) using CD34 and Periodic Acid-Schiff (PAS) double staining. To identify VM, slides were assessed for the presence of CD34-negative and PAS-positive channels indicating that they were not lined by endothelial cells. The histological staining pattern suggestive of VM was noted in 22/49 (44.9%) of the specimens studied. VM was observed in both recurring and non-recurring NFPAs. The incidence of VM present varied from case to case and within groups. There was no association between the presence of VM and gender, tumor size, Ki-67 index, recurrence or cavernous sinus invasion. VM was not noted in cases of non-tumorous pituitaries. Our findings suggest the existence of a complementary perfusion system in pituitary adenomas, implying potential clinical implications with respect to response to therapy and clinical course. Further research is warranted to confirm the presence of VM in pituitary adenomas to elucidate its clinical relevance in patients diagnosed with a pituitary adenoma. Mención de responsabilidad : Joseph Di Michele, Fabio Rotondo, Kalman Kovacs, Luis V Syro, George M Yousef, Michael D Cusimano, Antonio Di Ieva Referencia : Pathol Oncol Res. 2017 Oct;23(4):803-809. DOI (Digital Object Identifier) : 10.1007/s12253-017-0196-4 PMID : 28084580 En línea : https://link.springer.com/article/10.1007%2Fs12253-017-0196-4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4030 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000625 AC-2017-014 Archivo digital Producción Científica Artículos científicos Disponible
Título : IGF-I biomarker testing in an ethical context Tipo de documento : documento electrónico Autores : Beatriz Helena Aristizábal Bernal, Fecha de publicación : 2016 Títulos uniformes : Advances in Modern Oncology Research Idioma : Inglés (eng) Palabras clave : cancer biomarkers IGF-I gene testing bioethics Resumen : As we have come to know, there is a connection between cancer biomarkers and genes, along with their susceptibility to a particular disease, all of which have an obvious impact on the clinical practice and development of genetic testing. In any cancer disease, the diagnosis and treatment should be related to the investigation of specific biomarkers (generally antigens and proteins) and their corresponding genes. The study of different antigens such as alpha-fetoprotein, insulin-like growth factor I (IGF-I), insulin-like growth factor II, vascular endothelial growth factor, and epidermal growth factor, as well as their presence in neoplastic cells have demonstrated that IGF-I is an essential target for gene testing and therapeutic purpose. An over-expression of the IGF-I gene in mature tissues is a sign of neoplastic processes, e.g. brain or breast malignancy. A lot of questions have arisen regarding the ethics of gene testing, particularly concerns on the selection of patients for specific growth hormone/insulin-like growth factor I (GHIIGF-I) testing. Evidently, our current society is involved in a process of geneticization – the redefinition of individuals in terms of genetic codes. As such, we should take extreme care when making ethical judgments based on “scientific evidence” derived from genetic testing (typically those involving different biomarkers such as DNA, RNA, chromosomes, and proteins) in relation to genetic abnormalities that could predict current or future diseases. In this situation, the understanding of bioethics is of utmost importance. Mención de responsabilidad : Annabelle Trojan, Beatriz H. Aristizabal, Lina M. Jay, Tatiana Castillo, Pedro J. Penagos, Ignacio Briceño, Jerzy Trojan DOI (Digital Object Identifier) : 10.18282/amor.v2.i4.58 Derechos de uso : CC BY-NC En línea : http://www.advmodoncolres.sg/index.php/amor/article/view/66 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4655 IGF-I biomarker testing in an ethical context [documento electrónico] / Beatriz Helena Aristizábal Bernal, . - 2016.
Obra : Advances in Modern Oncology Research
Idioma : Inglés (eng)
Palabras clave : cancer biomarkers IGF-I gene testing bioethics Resumen : As we have come to know, there is a connection between cancer biomarkers and genes, along with their susceptibility to a particular disease, all of which have an obvious impact on the clinical practice and development of genetic testing. In any cancer disease, the diagnosis and treatment should be related to the investigation of specific biomarkers (generally antigens and proteins) and their corresponding genes. The study of different antigens such as alpha-fetoprotein, insulin-like growth factor I (IGF-I), insulin-like growth factor II, vascular endothelial growth factor, and epidermal growth factor, as well as their presence in neoplastic cells have demonstrated that IGF-I is an essential target for gene testing and therapeutic purpose. An over-expression of the IGF-I gene in mature tissues is a sign of neoplastic processes, e.g. brain or breast malignancy. A lot of questions have arisen regarding the ethics of gene testing, particularly concerns on the selection of patients for specific growth hormone/insulin-like growth factor I (GHIIGF-I) testing. Evidently, our current society is involved in a process of geneticization – the redefinition of individuals in terms of genetic codes. As such, we should take extreme care when making ethical judgments based on “scientific evidence” derived from genetic testing (typically those involving different biomarkers such as DNA, RNA, chromosomes, and proteins) in relation to genetic abnormalities that could predict current or future diseases. In this situation, the understanding of bioethics is of utmost importance. Mención de responsabilidad : Annabelle Trojan, Beatriz H. Aristizabal, Lina M. Jay, Tatiana Castillo, Pedro J. Penagos, Ignacio Briceño, Jerzy Trojan DOI (Digital Object Identifier) : 10.18282/amor.v2.i4.58 Derechos de uso : CC BY-NC En línea : http://www.advmodoncolres.sg/index.php/amor/article/view/66 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4655 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001351 AC-2016-138 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2016-138.pdfAdobe Acrobat PDF